GlassScriptPhysician profile
Walter Seth Ramsey
NPI 1689626509
$3,400.48
in general payments reported to CMS, 2019-2025
19 companies · $546 in 2025
The $546 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,253 · 2020: $51.32 · 2021: $300 · 2022: $414 · 2023: $480 · 2024: $356 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $1,218.17 | 2019-2022 | |
| Alcon Vision LLC | $779.79 | 2021-2025 | Simbrinza, Dailies Total1, Total30 |
| Bausch & Lomb Americas INC. | $378.75 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $189.91 | 2020-2025 | |
| Oyster Point Pharma, INC. | $154.29 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $119.58 | 2019 | |
| Abbvie INC. | $83.03 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $82.28 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $75.66 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $69.67 | 2021-2023 | Acuvue |
| Allergan, INC. | $60.72 | 2021-2022 | |
| Dompe US, INC. | $41.67 | 2024-2025 | Oxervate |
| Coopervision INC. | $32.51 | 2025 | Clariti Contact Lens, Myday Contact Lens |
| Lkc Technologies, INC. | $26.99 | 2023-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.46 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $16.28 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $14.84 | 2022 | |
| Biotissue Holdings INC. | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.